TCP-25 PU Dressing - An advanced bioactive wound dressing
| Reference number | |
| Coordinator | in2cure AB |
| Funding from Vinnova | SEK 1 445 000 |
| Project duration | September 2016 - November 2018 |
| Status | Completed |
Important results from the project
The purpose of the project was to develop and verify the effectiveness, regulatory pathway, and clinical potential of a novel wound dressing with anti-inflammatory and anti-infective effects. Of importance was also that we used generated data as input parameters for subsequent health economics analyses.
Expected long term effects
The effectiveness of TCP-25 gel was shown in large animal wound models. The subsequent health economics analyses showed that use of advanced dressings is a feasible approach in order to reduce total system costs for wound healing complications. On the regulatory side, we defined the regulatory pathway for TCP-25 products.
Approach and implementation
The project has included three parties, in2cure, Lund University and an industrial partner. The focus has been on evaluating in2cure´s wound treatment in large animal models, making a regulatory assessment of the concept, and evaluating the health-economic benefit of the treatment. The project has been regularly discussed in a steering committee with representatives from the various parties.